论文部分内容阅读
研究降钙素基因相关肽(CGRP)、神经肽y(NPY)与醛固酮(ALD)在门脉高压症发病中的作用。方法:应用放射免疫学方法对30例门脉高压症患者、30名正常对照者的血浆以及20例门脉高压症患者的腹水进行CGRP、NPY与ALD的检测。结果:门脉高压症组患者血浆CGRP、NPY与ALD水平分别为125.95±35.43pg/ml、88.49±52.51pg/ml及868.5±459.6pg/ml,正常对照组分别为69.14±23.29pg/ml、151.54±38.51pg/ml及306.4±124.3pg/ml,两组差别有显著意义(P<0.05),腹水组分别为81.83±38.55pg/ml、61.47±28.35pg/ml及216.7±186.1pg/ml。腹水CGRP与正常对照组相比差异无显著意义,腹水NPY与ALD含量低于正常对照组(P<0.05)。其中有腹水者NPY低于无腹水者,而CGRP与ALD水平高于无腹水者(P<0.05)。结论:血浆CGRP、NPY与ALD均在肝硬变门脉高压发病的病理生理机制中起作用。
To investigate the role of calcitonin gene-related peptide (CGRP), neuropeptide y (NPY) and aldosterone (ALD) in the pathogenesis of portal hypertension. Methods: CGRP, NPY and ALD were detected by radioimmunoassay in 30 patients with portal hypertension, 30 normal controls and ascites in 20 patients with portal hypertension. Results: The levels of plasma CGRP, NPY and ALD in patients with portal hypertension were 125.95 ± 35.43pg / ml, 88.49 ± 52.51pg / ml and 868.5 ± 459.6pg / ml, respectively, and those in the normal control group were 69.14 ± 23.29pg / ml, 151.54 ± 38.51 pg / ml and 306.4 ± 124.3 pg / ml, respectively. The difference between the two groups was significant (P <0.05). The ascites group was 81.83 ± 38.55pg / ml, 61.47 ± 28.35pg / ml and 216.7 ± 186.1pg / ml . The ascites CGRP compared with the normal control group was no significant difference, ascites NPY and ALD levels were lower than the normal control group (P <0.05). Among them, those with ascites had lower NPY than those without ascites, while CGRP and ALD were higher than those without ascites (P <0.05). Conclusion: Plasma CGRP, NPY and ALD play a role in the pathophysiological mechanism of cirrhosis with portal hypertension.